[HTML][HTML] Cabozantinib in progressive medullary thyroid cancer

R Elisei, MJ Schlumberger, SP Müller… - Journal of clinical …, 2013 - ncbi.nlm.nih.gov
R Elisei, MJ Schlumberger, SP Müller, P Schöffski, MS Brose, MH Shah, L Licitra, B Jarzab…
Journal of clinical oncology, 2013ncbi.nlm.nih.gov
Purpose Cabozantinib, a tyrosine kinase inhibitor (TKI) of hepatocyte growth factor receptor
(MET), vascular endothelial growth factor receptor 2, and rearranged during transfection
(RET), demonstrated clinical activity in patients with medullary thyroid cancer (MTC) in
phase I.
Abstract
Purpose
Cabozantinib, a tyrosine kinase inhibitor (TKI) of hepatocyte growth factor receptor (MET), vascular endothelial growth factor receptor 2, and rearranged during transfection (RET), demonstrated clinical activity in patients with medullary thyroid cancer (MTC) in phase I.
ncbi.nlm.nih.gov